Whats new

Whats new.

Baird - INSIGHT-003 Data Adds Support for Efti in NSCLC Ahead of Phase 3; Rated OP, US$7 PT (Analyst: Joel L. Beatty, MD)

November 14th 2024

For a copy of this research report please contact your Baird advisor

Go back